Next-generation precision oncology

Precision Oncology Biomarkers for ADCs and IO

We’re enabling smarter cancer treatment to ensure every patient gets their best possible therapy.
IMG_0360_EDIT

Our approach

Antibody-drug Conjugate Treatment Response Scores

Predictive biomarkers for benefit from a variety of approved and investigational antibody-drug conjugates (ADCs); based on a proprietary calculation method of three components including ADC target expression.

Immunotherapy Response Score

Immunotherapy Response Score is a pan-solid tumor predictive diagnostic tool for anti-PD-1/PD-L1 monotherapy benefit. This innovative biomarker algorithm captures the biology of the tumor and its microenvironment by combining tumor mutation burden (TMB) with quantitative expression of PD-L1, PD-1, ADAM12 and TOP2A.

Our Leaders

Dan Rhodes, PhD
Dan Rhodes, PhD

Co-Founder & CEO

Scott Tomlins, MD, PhD
Scott Tomlins, MD, PhD

Co-founder & Chief Medical Officer

Catherine Sazdanoff
Catherine Sazdanoff

Chief Business Development Officer & Chief Compliance and Legal Officer

Bryan Johnson
Bryan Johnson

Chief Data Scientist

Matt Martin, MBA
Matt Martin, MBA

Chief Financial Officer

ScottN
Scott Nisbet

VP, Business Development

Our Investors

Investor Logos=Wellington Management Logo Investor Logos=Cormorant Asset management Logo Investor Logos=Arboretum Logo Investor Logos=Merck Logo Investor Logos=HighSide Capital Managment Logo Investor Logos=Pfizer Logo Investor Logos=Monashee Investment Management Logo Investor Logos=Renaissance Venture Capital Logo Investor Logos=Deerfield Logo Investor Logos=Baird Capital Logo

Our Values

About us 4
1/7

Start with the patient

Focus on the patient first and all else will follow.

2/7

Think big

We never settle — in everything we do, we push against boundaries and think boldly to achieve life-changing results for patients.

3/7

Embrace the journey.

Building the leading precision oncology company requires unrivaled vision, innovation and execution. We take pride in our work and celebrate wins along the way.

4/7

Apply a scientific mindset

We move quickly and deliberately, using a logical and data-driven approach to guide our decisions and achieve breakthroughs. We hold ourselves mutually accountable to achieving transformative results.

5/7

Best idea wins

We challenge assumptions to foster innovation and create the best possible solution. In doing so, we actively listen with humility and respect.

6/7

Strive for the highest bar

Given our responsibility to each other and patients with cancer, we expect excellence and integrity in all that we do. We do the right thing because there is no alternative.

7/7

Have fun & embrace the team

We collaborate and celebrate. We believe in building relationships with our coworkers because greatness comes from unlocking each other’s potential.

In the news

The latest from Strata Oncology

December 1, 2023

Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium

Read more
November 8, 2023

Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards

Read more
September 11, 2023

Dr. Nair on the clinical utility of Immunotherapy Response Score 

Read more
September 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

Read more
September 7, 2023

Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer

Read more